Phosphatidylethanolamine (18:2e/18:2) may inhibit adipose tissue wasting in patients with cancer cachexia by increasing lysophosphatidic acid receptor 6

•Cancer Cachexia Dynamics: Profound lipid alterations unveiled in subcutaneous and visceral adipose tissues.•Ceramide Imbalance: Cachectic patients exhibit elevated Ceramide levels, underscoring lipid dysregulation.•LPAR6 Modulation: LPAR6 emerges as a pivotal player, elevated in both adipose tissues of cachectic patients.•Pathway Enrichment: Shared lipids correlate with weight loss and IL-6 levels, enriched in key metabolic pathways.•Therapeutic Prospects: PE(18:2e/18:2) identified as a potential modulator, offering insights for targeted interventions.